The Value of IVL Compared To OPN Non-Compliant Balloons for Treatment of RefractorY Coronary Lesions (VICTORY) Trial

NARecruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

November 22, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

May 30, 2028

Conditions
Coronary DiseaseCoronary Artery DiseaseCalcific Coronary ArteriosclerosisStent RestenosisCoronary Artery Calcification
Interventions
DEVICE

OPN™ NCB Super High Pressure PCI Balloon

"In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion."

DEVICE

Shockwave™ C2 IVL Catheter

"In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion."

Trial Locations (1)

6000

RECRUITING

Luzerner Heart Centre, Lucerne

All Listed Sponsors
collaborator

Hôpital Fribourgeois

OTHER

collaborator

Hamilton General Hospital

UNKNOWN

lead

Luzerner Kantonsspital

OTHER